Xconomy | Seattle - Business + Technology in the Exponential Economy

Seattle Genetics Drug Passes Safety Test, Trial Continues

Seattle Genetics said today its experimental drug for acute myeloid leukemia passed an interim safety review. The Bothell, WA-based biotech company (NASDAQ: SGEN) said an independent monitoring committee recommended the study continue of lintuzumab (SGN-33). Full results from the trial, which is two-thirds of the way to its enrollment goal of 210 patients, should be available in the first half of 2010, the company said.

Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.

Comments | Reprints | Share: